Cannabinoids delivery systems based on supramolecular inclusion complexes and polymeric nanocapsules for treatment of neuropathic pain

Cannabinoids (CBs) and particularly CB2 agonists have been shown to reduce pain andinflammation without eliciting any apparent psychotropic effect conversely to CB1agonist compounds. CBs candidates are usually lipophilic non drug-like compoundswith poor bioavailability. To serve the purpose of evalu...

Full description

Bibliographic Details
Main Author: Astruc-Diaz, Fanny
Language:ENG
Published: Université Claude Bernard - Lyon I 2012
Subjects:
Online Access:http://tel.archives-ouvertes.fr/tel-00935588
http://tel.archives-ouvertes.fr/docs/00/93/55/88/PDF/TH2012DiazFanny.pdf
id ndltd-CCSD-oai-tel.archives-ouvertes.fr-tel-00935588
record_format oai_dc
spelling ndltd-CCSD-oai-tel.archives-ouvertes.fr-tel-009355882014-01-25T03:20:33Z http://tel.archives-ouvertes.fr/tel-00935588 2012LYO10099 http://tel.archives-ouvertes.fr/docs/00/93/55/88/PDF/TH2012DiazFanny.pdf Cannabinoids delivery systems based on supramolecular inclusion complexes and polymeric nanocapsules for treatment of neuropathic pain Astruc-Diaz, Fanny [SDV:MHEP] Life Sciences/Human health and pathology [SDV:MHEP] Sciences du Vivant/Médecine humaine et pathologie Cannabinoids CB2 agonists receptors Cyclodextrin Cationic polymeric nanocapsules Phytocannabinoid Cannabinoids (CBs) and particularly CB2 agonists have been shown to reduce pain andinflammation without eliciting any apparent psychotropic effect conversely to CB1agonist compounds. CBs candidates are usually lipophilic non drug-like compoundswith poor bioavailability. To serve the purpose of evaluating new synthetic CB2 agonistsdeveloped by our group, on in vivo neuropathic pain models, an enabling formulationstrategy has been set up and four Drug Delivery Systems (DDS) developed. Forparenteral administration, cyclodextrin (CD)-based inclusion complexes, liposomes andsurfactants/co-solvents micellar solution have been investigated whereas Self-Emulsifying DDS (SEDDS) was selected for oral administration. A pharmacologicalstudy conducted with lead compound MDA7, formulated in CD-based DDS resulted inthe higher antinociceptive activity. A comprehensive study of the inclusion mechanismof MDA7 in the CD supramolecular complexes prepared was carried out. MDA7pharmacokinetic profile was also generated formulated in micellar solution and SEDDS.Besides, cationic polymeric nanocapsules (NCs) have been designed to serve as aprotective DDS for oral administration of a dietary phytocannabinoid CB2 agonist.Studies were undertaken to characterize and evaluate the influence of differentparameters on NCs formation prepared by nanoprecipitation. The cationic NCsdeveloped have been explored for their property to yield proportion of counterioniccondensation in the presence of macrocycles bearing anionic groups such assulfobutylether-beta-cyclodextrin or to form electrostatic interactions/host-guestcomplexion with cucurbit[n]uril. 2012-07-09 ENG PhD thesis Université Claude Bernard - Lyon I
collection NDLTD
language ENG
sources NDLTD
topic [SDV:MHEP] Life Sciences/Human health and pathology
[SDV:MHEP] Sciences du Vivant/Médecine humaine et pathologie
Cannabinoids
CB2 agonists receptors
Cyclodextrin
Cationic polymeric nanocapsules
Phytocannabinoid
spellingShingle [SDV:MHEP] Life Sciences/Human health and pathology
[SDV:MHEP] Sciences du Vivant/Médecine humaine et pathologie
Cannabinoids
CB2 agonists receptors
Cyclodextrin
Cationic polymeric nanocapsules
Phytocannabinoid
Astruc-Diaz, Fanny
Cannabinoids delivery systems based on supramolecular inclusion complexes and polymeric nanocapsules for treatment of neuropathic pain
description Cannabinoids (CBs) and particularly CB2 agonists have been shown to reduce pain andinflammation without eliciting any apparent psychotropic effect conversely to CB1agonist compounds. CBs candidates are usually lipophilic non drug-like compoundswith poor bioavailability. To serve the purpose of evaluating new synthetic CB2 agonistsdeveloped by our group, on in vivo neuropathic pain models, an enabling formulationstrategy has been set up and four Drug Delivery Systems (DDS) developed. Forparenteral administration, cyclodextrin (CD)-based inclusion complexes, liposomes andsurfactants/co-solvents micellar solution have been investigated whereas Self-Emulsifying DDS (SEDDS) was selected for oral administration. A pharmacologicalstudy conducted with lead compound MDA7, formulated in CD-based DDS resulted inthe higher antinociceptive activity. A comprehensive study of the inclusion mechanismof MDA7 in the CD supramolecular complexes prepared was carried out. MDA7pharmacokinetic profile was also generated formulated in micellar solution and SEDDS.Besides, cationic polymeric nanocapsules (NCs) have been designed to serve as aprotective DDS for oral administration of a dietary phytocannabinoid CB2 agonist.Studies were undertaken to characterize and evaluate the influence of differentparameters on NCs formation prepared by nanoprecipitation. The cationic NCsdeveloped have been explored for their property to yield proportion of counterioniccondensation in the presence of macrocycles bearing anionic groups such assulfobutylether-beta-cyclodextrin or to form electrostatic interactions/host-guestcomplexion with cucurbit[n]uril.
author Astruc-Diaz, Fanny
author_facet Astruc-Diaz, Fanny
author_sort Astruc-Diaz, Fanny
title Cannabinoids delivery systems based on supramolecular inclusion complexes and polymeric nanocapsules for treatment of neuropathic pain
title_short Cannabinoids delivery systems based on supramolecular inclusion complexes and polymeric nanocapsules for treatment of neuropathic pain
title_full Cannabinoids delivery systems based on supramolecular inclusion complexes and polymeric nanocapsules for treatment of neuropathic pain
title_fullStr Cannabinoids delivery systems based on supramolecular inclusion complexes and polymeric nanocapsules for treatment of neuropathic pain
title_full_unstemmed Cannabinoids delivery systems based on supramolecular inclusion complexes and polymeric nanocapsules for treatment of neuropathic pain
title_sort cannabinoids delivery systems based on supramolecular inclusion complexes and polymeric nanocapsules for treatment of neuropathic pain
publisher Université Claude Bernard - Lyon I
publishDate 2012
url http://tel.archives-ouvertes.fr/tel-00935588
http://tel.archives-ouvertes.fr/docs/00/93/55/88/PDF/TH2012DiazFanny.pdf
work_keys_str_mv AT astrucdiazfanny cannabinoidsdeliverysystemsbasedonsupramolecularinclusioncomplexesandpolymericnanocapsulesfortreatmentofneuropathicpain
_version_ 1716627434582835200